Remove 2026 Remove FDA Remove Patient Care
article thumbnail

Expert Discusses McKesson's Approach to Supporting Community Pharmacies | McKesson ideaShare

Drug Topics

"I think it's really important, as we move to 2026 and beyond, we figure out ways to help pharmacies ease that burden and diversify their business." Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips. Subscribe Now!

article thumbnail

Passport to Protection: Best Practices for Travel Vaccines in the Pharmacy Setting

Drug Topics

Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? 2026 Edition. To read these stories and more, download the PDF of the Drug Topics May/June issue here. Sign up today for our free Drug Topics newsletter. REFERENCES 1. Yellow Book. Updated April 23, 2025.

Vaccines 341
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hair Loss Therapy Shows Potential for Regeneration in Phase 2 Trial

Drug Topics

Positive results have been announced from a phase 2a clinical trial evaluating the safety, pharmacokinetics and efficacy of PP405 for the treatment of androgenetic alopecia in adult patients, Pelage Pharmaceuticals announced in a release. 1 The company said it plans to initiate phase 3 studies in 2026 to further evaluate the therapy.

article thumbnail

DSCSA Postponement And What It Means For Independent Pharmacies

DiversifyRx

Small Dispensers and the 6/12/2024 FDA Announcement Concerning DSCSA This week’s article on the recent DSCSA postponement comes from PRS Pharmacy Services. The exemption will last until November 27, 2026, for those small dispensers who qualify. We need more clarity here to see what the FDA is planning.

article thumbnail

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

Drug Topics

The FDA has accepted for review a New Drug Application (NDA) for doravirine/islatravir for adult patients with HIV-1 infection that is virologically suppressed on antiretroviral therapy, Merck announced in a release. 1 The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026. References 1.

FDA 247
article thumbnail

Turning Reconciliation into a Revenue Growth Engine

Drug Topics

With rising drug costs, evolving health care regulations, and challenging reimbursement models, pharmacies must adopt strategic approaches to maintain financial health and continue providing patient care.

article thumbnail

FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants

Drug Topics

The FDA approved clesrovimab-cfor (Enflonsia) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season, Merck announced in a release. READ MORE: Infectious Disease Resource Center Pharmacy practice is always changing. References 1.

FDA 430